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THE EFFECT ON TREATMENT RESPONSE OF FIBROMYALGIA 
SYMPTOMS IN EARLY RHEUMATOID ARTHRITIS PATIENTS: 
RESULTS FROM THE ESPOIR COHORT 
JOSEFINA DURAN SANTA CRUZ 
ABSTRACT 
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that can 
lead to important functional impairment. Although improvements in treatment 
have been made, still there are a high proportion of patients in whom response to 
treatment is not complete. Fibromyalgia (FM) is a condition characterized by 
bodily pain that often coexists with RA. Cross-sectional studies have shown that 
patients with RA and FM symptoms, or fibromyalgic RA (FRA), have higher 
disease activity scores than patients with RA and no FRA. Concern has been 
raised regarding the validity of RA disease activity scores in patients with 
coexistent RA and FM. In this prospective study, we hypothesized that patients 
with FRA have an impaired response to treatment measured by traditionally used 
scores.  
The present analysis used a study sample obtained from the ESPOIR French 
cohort. This is a longitudinal prospective cohort of adults with early RA. Patients 
with RA were classified in two groups according to the presence of FRA. RA 
disease activity scores (DAS28, SDAI, CDAI and HAQ) were compared as a 
measure of response to treatment at 6, 12 and 18 months. Results showed that 
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after adjusting for confounders, patients with FRA (120) had higher activity 
scores than patients with RA and no fibromyalgic characteristics (548). DAS28 
and other disease activity scores started out higher in subjects with FRA and 
while they improved to a similar extent as in the isolated RA group, they 
remained consistently higher among FRA patients. Achievement of low disease 
activity and of remission according to established activity score cut-points was 
significantly less likely in subjects with FRA. In conclusion, patients with FRA and 
RA had a similar response to treatment according the decrease in indexes of 
disease activity but more frequently missed the target of remission or low disease 
activity. These findings may have implications in RA treatment in patients with 
FRA, as therapy is escalated not in relation to change in scores but to achieving 
remission.  
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that 
affects 0.5%-1% of the population [1]. The pain and physical limitation it 
produces severely compromise functioning, generating work disability in 30-50% 
of patients at 10 years. [2, 3, 4] 
A “treat-to-target“ strategy has been shown to improve outcomes and is 
advocated in early RA to tailor treatment [5]. This strategy is based on the use of 
activity scores to define remission or low disease activity (LDA) and adjust 
treatment according to these aims. DAS28 has been the most studied and used 
score. [6] This score gives a particularly high weight to tender joint counts (TJC) 
versus swollen joint counts (SJC). This may lead to classifying patients as having 
active disease based mainly on tenderness.[7] While they do include TJC and 
SJC, the Simple Disease Activity Index (SDAI) and the Clinical Disease Activity 
Index (CDAI) do not give differential weights to these joint count measures. [8] 
With advances in RA treatment, remission is an achievable target. However, 
regardless of how remission is defined, a majority of patients still have some 
residual disease activity [9]. Although several factors that predict a poor response 
to therapy have been identified, there is limited capacity to anticipate who will 
require aggressive management. [10, 11] Drugs used in RA are associated with 
important adverse events and potentially substantial costs; therefore it is crucial 
to determine who will truly benefit from intense therapy. [12, 13, 14] 
	  	  
2 
Fibromyalgia (FM) often coexists with RA. [15] The prevalence of FM in 
the general population is 2.7-5.1% and in RA it reaches a prevalence of up to 
20%.[16, 17, 18, 19]. Concern has been raised regarding the validity of RA 
disease activity scores in patients with coexistent RA and FM, making a “treat-to-
target“ strategy questionable in these patients. [20] Cross-sectional studies have 
shown that FM patients have higher DAS28, higher TJC, worse self-reported 
global health (GH), and worse functional impairment. [21, 21, 23, 24] Regarding 
“fibromyalginess” without meeting FM criteria, a study by Wolfe et al. using the 
National Data Bank for rheumatic diseases evaluated the effect of the spectrum 
of FM symptoms measured using the PSD (polysymptomatic distress scale) on 
response to therapy in RA patients (REF). This study showed that with increasing 
PDS, clinical variables became more abnormal, including CDAI. In addition, the 
greater the PSD score the more patient-reported response variables 
predominated over physician and laboratory measurements, particularly when 
using composite measures. Authors of this study concluded, “It is not necessary 
for fibromyalgia criteria to be satisfied for these effects to take place”. [25] 
Tender points are part of the 1990 ACR classification criteria traditionally 
used to diagnose FM, with a cutpoint of ≥11 tender points. [26] However 
measuring them is time consuming and not always performed in RA clinics. An 
index was developed by Pollard et al to identify “fibromyalgic RA” (FRA) using 
RA patients’ physical examination measures instead of tender points to diagnose 
it. This score was developed in a RA cohort in which the relationship of TJC 
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minus SJC had a ROC area under the curve of 0.86 to predict FM, and TJC-SJC 
≥7 predicted the presence of ≥11 tender points with 83% sensitivity and 80% 
specificity. The score was validated in a replicate cohort with high sensitivity and 
specificity (72% and 98%) for FM. [27] 
Worse disease activity in FRA could be a consequence of a blunted 
response to RA treatment or it could be due to the effect of persistent tenderness 
and fibromyalgia symptoms on disease activity measures.   If response to 
treatment is poor, then the treat to target approach might need to be 
reconsidered in this large subset of patients. To our knowledge, no prospective 
longitudinal studies that have followed patients from beginning of treatment have 
been carried out to address this question.  
In this prospective study, using the TJC-SJC index to characterize the 
presence of fibromyalgic RA, we hypothesized that patients with this condition 
have an impaired response to treatment measured by traditionally used scores. 
In spite of this, we postulate they do not have increased structural damage.  
 
MATERIALS AND METHODS. 
Study Subjects We addressed our questions using the ESPOIR cohort, a 
prospective multi-center early arthritis cohort. This cohort included patients aged 
18–70 years, with 2 or more swollen joints with a duration of joint swelling of > 6 
weeks and < 6 months, no previous disease-modifying drugs (DMARDS), no 
previous steroids, and no definite diagnosis of a disease other than RA or 
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undifferentiated arthritis.[28] In our study, we included only patients with RA 
defined by the 1987 ACR and/or the 2010 ACR/EULAR classification criteria. Our 
inclusion criteria required a subject to meet either of the aforementioned criteria 
and have a TJC and SJC performed at the baseline visit. We excluded 
participants classified as having undifferentiated arthritis, and those with missing 
values of DAS28, SDAI or CDAI at baseline and at all follow up visits.  
 
Exposure: Presence of FRA was defined at baseline as having a TJC–SJC ≥7. 
[27] This represented our exposure. Participants were classified into two groups 
according to the presence or absence FRA. We shall label this latter group 
“isolated RA”. 
 
Study outcomes The main outcome of this study was response to treatment in 
subjects with and without FRA. Response to treatment was defined using activity 
score measures in RA, including DAS28, CDAI, SDAI and HAQ. In addition the 
core components of DAS28 were evaluated.  
 Our secondary outcomes were the attainment of low disease activity 
(LDA) according to DAS28 (DAS28≤3.2) and of remission according to DAS28 
(≤2.6), CDAI (CDAI≤2.8) and SDAI (SDAI≤3.3). In addition, SHARP score was 
compared at baseline and 12 months. Finally, treatment during follow-up was 
compared among the two groups. 
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Analytic approach:  
Baseline characteristics: At baseline, differences in demographics between 
study groups were explored including age, gender, race, body mass index (BMI), 
and smoking status (defined as current or past smokers vs never smokers). BMI 
was categorized as obese (BMI≥30kg/m2) vs non-obese (BMI<30kg/m2). In 
addition, a comparison of RA characteristics was performed: serologic markers 
(rheumatoid factor (RF) and anti-cyclic Citrullinated Peptide (anti-CCP), TJC, 
SJC and presence of erosions (none vs. one or more) evaluated in bilateral 
hands and feet radiographs. RA activity scores including DAS28, CDAI and SDAI 
were calculated as well as HAQ (Health Assessment Questionnaire) to evaluate 
functional impairment and the van der Heijde-modified total Sharp radiologic 
score (mTSS). Drugs were classified as analgesics, non-steroidal anti-
inflammatory drugs (NSAIDS), oral corticosteroids, monotherapy with non-
biologic DMARDS, combination of non-biologic DMARDS, monotherapy with 
biologic DMARDS, and combination of non-biologic with biologic DMARDS. 
Baseline characteristics are reported as number (%) or mean±SD. A two sample 
T-Test was used to compare quantitative variables and a χ2 test (or Fisher’s 
exact test) for categorical variables. 
 
Outcomes: All outcomes were compared at six, twelve and eighteen months of 
follow-up between patients who were classified as having FRA versus patients 
with isolated RA. DAS28 and its core measurements was the main outcome. 
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Also, CDAI, SDAI and HAQ were compared. These outcomes were compared at 
each time-point between the two groups (FRA vs. no FRA) using a mixed linear 
regression model for repeated measures. We adjusted for the baseline value of 
the outcome being measured as well as other potential confounders: gender, age 
and smoking status. This model was used for activity scores as well as score 
components. Each of the score’s components was analyzed including SJC, TJC, 
physician global health (phGH) visual analogue scales (VAS), patient global 
health (ptGH) VAS, C-reactive protein and ESR.  
As secondary outcomes an analysis was performed of the attainment 
DAS28 LDA (DAS28<3.2) and of remission according to DAS28 (≤2.6), CDAI 
(CDAI≤2.8) and SDAI (SDAI≤3.3). Additionally, treatment during follow-up was 
compared using the same categorical classification as in the baseline 
characteristics’ analysis. 
We examined the risk of attaining all secondary outcomes in each of our 
study groups at each of the time-points (6, 12, 18 months) using a log binomial 
regression with an estimation of risk ratios (RRs) with repeated measurements. 
RRs were obtained using a generalized estimating equation (GEE) model to 
adjust for multiple observations per subject.  
Lastly, to evaluate structural damage, mTSS was evaluated at 12 months using a 
two sample T-test.  
For all analysis, a p<0.05 was considered statistically significant. SAS 9.3 
was used to perform all statistical calculations. 
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Power calculation: 
We had 99% power to detect a DAS28 difference between groups of 0.5, 
considering a standard deviation of 1.3 using 120 subjects with FRA and 548 
without, 3 visits per subject and an intraclass correlation coefficient for repeated 
measures of DAS28=0.6. 
 
RESULTS 
Baseline Patient Characteristics 
There were 697 subjects with RA at baseline among the 813 ESPOIR 
cohort participants.  Of these, 24 did not come to any of the follow-up visits and 
were excluded. We further excluded 5 subjects with all activity scores missing at 
follow-up. As a consequence, 668 subjects were included in the analysis. (Figure 
1)  
Subjects had a mean age of 48.3 years at baseline, 76.1% were females 
and 92.1% Caucasian. There were 47.3% ever smokers (see table 1). At 
baseline, patients had active disease with a mean DAS28 of 5.32.  Erosions were 
present in 63.6% of patients.  
FRA was present in 120 (17.96%) patients. There was no significant 
difference in baseline demographic characteristics according to the presence of 
FRA (see Table1). However, patients with FRA met ACR/EULAR 2010 RA 
criteria more frequently than patients without FRA (p=0.04), with no difference in 
ACR 1987 criteria (p=0.54). They also had a lower frequency of seropositivity 
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(RF and antiCCP) (p=0.0003).  
RA activity scores and HAQ were higher in the FRA group. Also, TJC and 
GH evaluation by the physician and the patient were higher in these patients. On 
the other hand, ESR and the mTSS score were significantly lower in spite of the 
presence of higher activity scores. There were no differences in use of 
medications of any kind (Table 1). 
 Patients with missing values in any visit did not have significant 
differences in baseline characteristics from those without missing values. 
 
Activity scores in FRA patients over time.  
In a multivariate analysis incorporating the three study visits, adjusting for 
the baseline score, we found that patients with FRA had a higher DAS28 than 
patients with isolated RA (p<0.0001). DAS28 scores started out higher in 
subjects with FRA and while they improved to a similar extent as in the isolated 
RA group, they remained consistently higher among FRA subjects. In none of the 
visits in FRA subjects did the average DAS28 score reach LDA (Figure 2). It is 
noteworthy that although TJC showed an important decrease in both groups after 
treatment, they remained significantly higher in subjects with FRA. Patient and 
physician global health scores also remained worse in the FRA group at follow-
up. On the other hand, SJC decreased to such an extent in both groups that 
there was no difference between them during follow-up. Regarding inflammatory 
parameters (ESR and CRP), there was no difference between groups after 
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treatment. (Figure 3) (Figure 4) 
As shown in Table 2, other activity scores including SDAI, CDAI and HAQ 
were also higher in the group with FRA. These scores had a similar behavior as 
DAS28, starting higher and presenting a similar decrease in both groups (data 
not shown). In contrast, mTSS score was similar between groups during follow 
up (Table 2). 
The overall achievement of LDA at 6, 12 and 18 months was significantly 
less likely in subjects with FRA, with a RR of 0.77 (95% confidence interval CI 
0.63-0.94). Also there was less attainment of remission according to DAS28 and 
SDAI in this study group: RR=0.61 (95%CI 0.46-0.81) and 0.65 (95%CI 0.43-
0.97) respectively. FRA patients had a modestly lower risk of achieving CDAI 
remission too: RR=0.70,with a borderline p value=0.06. (Table 3) 
 
Association between FRA and therapy. 
We did not find an association between FRA and analgesic use with an 
estimated RR=1.12 and a p value=0.0705. Also no association was identified 
with NSAIDS nor corticosteroids with an RR=1.0 (p value=0.9759) and an 
RR=1.07 (p value=0.4785), respectively. Non-biologic DMARDS both as 
monotherapy and combination therapy were also not associated with the 
presence of FRA (RR=0.82, p=0.98 and RR=0.53, p=0.9205. Finally, no 
difference existed in the use of biologic DMARDS as monotherapy (RR=0.26, 
p=0.2928) and combined with non-biologic DMARDS (RR=0.52, p=1.222). 
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DISCUSSION 
 In this cohort, subjects with FRA had higher baseline DAS28, CDAI, SDAI 
and HAQ than those with isolated RA. In addition, although FRA subjects 
improved with treatment to a similar extent as subjects without FRA, they 
maintained higher scores after treatment at all time-points. TJC also continued to 
be higher in participants classified as having FRA. In contrast, SJC, acute phase 
reactant levels, and mTSS scores were higher in subjects with isolated RA at 
baseline, but there was no difference between groups in both measures at follow-
up. Therefore, both activity scores and core measurements decreased after 
treatment in both groups, reflecting that a response to therapy existed in all 
patients, but TJC and activity scores values remained higher in subjects with 
FRA. 
 In the only other study examining a similar issue in a longitudinal study, 
Andersson et al. addressed the question of response to treatment in RA patients 
with chronic widespread pain (CWP), a condition in the same spectrum of 
conditions as FM. They classified patients as having CWP based on self-report of 
pain in all four body quadrants at nine years of follow-up and retrospectively 
looked at response to treatment in an earlier five year period.  They found that 
patients with CWP had worse disease activity scores after having been 
treated.[29] Patients with active RA without FRA could have met their definition of 
CWP, and the number of RA patients in this subset in their study (34%) was 
larger than any other subset and much higher than the usual estimate of 10-20% 
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for FM raising questions as to whether all of these patients had FRA.  
 Our baseline findings are concordant with previous cross-sectional 
studies. [21, 22, 23, 24, 25] One important question is if the traditionally used 
scores reflect more active RA or if scores in patients in the fibromyalgic spectrum 
do not necessarily measure RA activity, but a mixture of RA and fibromyalgia-like 
symptoms. The reliability of DAS28 has been shown to be inferior in patients with 
FM. [30] 
It could be argued that our finding of a higher baseline DAS28 is 
secondary to our definition of FRA. However, while DAS28 gives more weight to 
TJC than SJC, CDAI and SDAI do not and these two scores were also higher in 
patients with FRA. Still, all of these scores include TJC and a Global health 
measure and it has been shown they are influenced by the patient’s pain 
perception. [31]  
 The HAQ score, which does not include TJC, measures functional 
limitation and is also higher in patients with FRA. This score is probably affected 
by the symptoms generated by FRA per se and not necessarily due to more 
aggressive RA. 
When analyzing response to treatment, at first impression the fact that 
activity scores continued to be higher in the FRA groups can be interpreted as a 
poor response to therapy. However, the decrease in score was similar in both 
groups (Figure 2), and patients with FRA had higher baseline values. Therefore, 
patients with FRA do respond to treatment, but have persistently higher activity 
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scores. The maintenance of scores could have two explanations. First, because 
DAS28 weights TJC more than SJC, it is more likely that patients with FRA would 
be assessed as continuing to have activity due to pain which may be secondary 
to FRA and not RA disease activity. It has been shown that patients with FRA 
can have no clinical evidence of inflammation and still be categorized as active 
by DAS28. [7] On the other hand, patients with FRA may have central 
sensitization that may in turn affect their response to therapy regarding pain 
control. [32, 33, 34] As a consequence, high disease activity scores may be 
produced by a diminished response of pain in patients with FRA and not 
necessarily because of a lack of accuracy of scores. In either situation, this 
instrument could misclassify patients as having inflammation. It is noteworthy that 
although at study initiation the existence of higher TJC could be related to our 
definition of FRA, during follow up TJC as well as SJC decreased in both groups, 
showing that they do respond to therapy, but there is residual pain in patients 
who have a fibromyalgic spectrum that prevents them from reaching LDA or 
remission. The TJC scores continued to be higher in FRA patients at follow-up 
after controlling for baseline values. The same occurred with the Global Health 
measure. Nevertheless, there was no difference in SJC and ESR between the 
two groups after treatment, two elements that do not rely on patient reports to 
characterize active RA.  
Finally, the fact that modified Sharp scores were not higher in patients with 
FRA supports the hypothesis that patients’ activity scores in this group do not 
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reflect only RA activity, although the follow-up period may be too short to 
evaluate radiologic differences between groups. 
Remission and LDA were less frequently achieved in patients with FRA 
(Figure 2). The classification of patients as having active disease could lead to 
escalating the intensity of treatment of RA. Treatment for arthritis is aimed at 
controlling inflammation and in patients with FRA these scores may reflect pain 
and not necessarily inflammation. As a consequence, patients with FRA may be 
overtreated using a “treat-to-target” strategy. This would increase the risk of 
adverse events and cost. Since current target score values are unlikely to be met 
in FRA patients, a less stringent target may need to be established for this group. 
On the other hand, the drug algorithm that treatment guidelines using “treat-to-
target” propose, could be modified in cases that high activity scores are caused 
by high pain, focusing more on analgesic treatment. [5, 35] McWilliams et al. 
have created a score called DAS28-P that focuses in TJC and ptGH and that 
was shown to predict bodily pain at 12 months. [36] Although it needs further 
validation, this could be used in patients with FRA. Similarly, Kristensen et al. 
showed in a prospective study that a SJC/TJC ratio predicted response to 
antiTNF in patients refractory to traditional DMARDS. [37] This ratio could 
represent a way to categorize patients regarding response to treatment in 
presence of CWP, a condition that shares many properties with FRA. 
The definition we used of FRA could generate misclassification of patients 
with RA who have high disease activity as having FRA, when this is not the case. 
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However, given the diagnostic performance of the TJC-SJC measure [27], it is 
unlikely especially since there are not many false positives (i.e. the specificity of 
this approach is high) and the use of TJC-SJC should be a valid representation 
of persons with FRA. Further, the maintenance of the TJC and SJC discordance 
in these patients argues against this misclassification phenomenon (Figure 4). 
On the other hand, given the sensitivity if the difference in joint counts to detect 
FRA some patients could have been missed. If this were the case our estimate 
would have been biased towards the null so this does not invalidate our findings. 
One limitation of our work is that the disease activity scores we used may 
generate misclassification of our outcome of response to treatment.  DAS28, in 
particular, has been shown to allow for inflammation to exist in a state of 
remission.[38, 39, 40] The new ACR/EULAR remission criteria avoid this 
misclassification but SDAI, which is an index recommended by these criteria, 
showed the same results as DAS28 in our study. [41] The ACR/EULAR Boolean 
definition of remission could also generate misclassification in FRA patients 
because patient global assessment has been shown to be the factor that more 
frequently prevents remission from being attained. [42]. Another limitation of our 
work is that we did not formally evaluate patients for fibromyalgia. It is likely that 
those with FRA include many with fibromyalgia, but others may not have had 
comorbid fibromyalgia, and it is also possible that a number of persons with 
coexistent fibromyalgia and RA were not captured by our approach. 
Loss to follow up, considered as missing all visits was extremely low 
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(3.6%) and there was no difference between these patients and patients 
analyzed. Therefore, it is unlikely to represent a source of selection bias.  
In relation to confounding, we adjusted for the main known confounder 
age, smoking and gender. However other confounders may exist such as 
socioeconomic status, depression and/or anxiety disorders, comorbidities, 
alcohol use and unknown confounders.  
Although adjusting for baseline score values could have generated bias if 
fibromyalgic symptoms preceded the baseline measurements in this case we 
considered it necessary to adjust for these values given that RA high scores is 
associated with a higher frequency of fibromyalgia symptoms. The fact that the 
prevalence of FRA in our population corresponds to the prevalence in an RA 
population leads to the conclusion that RA activity was present before the 
classification of patients as having FRA. The analysis was also performed 
excluding the baseline score term and findings did not change (data not shown).  
Finally, in relation to generalizability, this study was performed in a mainly 
Caucasian population and in a country where there is a good access to second 
line treatment in RA. However, the study the effect of fibromyalgic symptoms on 
disease scores and this is unlikely to be affected by these conditions. Therefore 
our results should be applicable to RA patients in general.  
The fact that RA may cause central sensitization and therefore FRA 
makes it difficult to determine if it is the coexistence of FRA that determines less 
response to treatment or if it is explained by patients that have an aggressive 
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form of RA developing FRA more frequently [43]. The ESPOIR cohort’s short 
duration of disease at baseline makes it less likely, although not impossible, that 
at baseline a chronic sensitization phenomenon due to RA existed.[44, 45] In 
addition, this would not invalidate our findings that in patients that FRA exists, 
regardless of its origin, scores will have a worse response to therapy.   
 
Conclusion 
In conclusion, patients with FRA have a worse response to treatment according 
to traditional disease activity scores with respect to the absolute final value 
achieved rather than the relative decrease in score. However, RA inflammation 
may be responding as the scores drop and the residual activity measured could 
correspond mainly to residual pain related to FRA. We must reconsider the use 
of a treat-to-target strategy, as it is currently defined, in patients with FRA.    
  
	  	  
17 
 All 
(n=668) 
FRA 
(n=120) 
No FRA 
(n=548) 
P Value* 
Female Gender  %,  76.1 82.5 74.6 0.068 
Age, mean(SD) 48.3 (12.1) 47.6 (12.5) 48.5(12.1) 0.48 
Race (Caucasian,%) 92.1 91.7 92.2 0.86 
Smokers  (%) 47.3 49.2 46.9 0.65 
Obesity  (%) 14.4 15.8 14.1 0.61 
ACR 1987 (%) 83.5 81.7 83.9 0.54 
ACR/EULAR2010 (%) 93.4 97.5 92.5 0.045 
DAS 28, mean (SD) 5.32 (1.24) 6.02 (0.92) 5.16 (1.25) <0.0001 
CDAI, mean (SD) 28.77(13.33) 37.94 (10.38) 26.76 (13.06) <0.0001 
SDAI, mean(SD) 31.0 (14.45) 39.78 (11.37) 29.09 (14.35) <0.0001 
HAQ, mean (SD) 1.03 (0.69) 1.25 (0.68) 0.98 (0.68) <0.0001 
SJC, mean (SD) 7.99 (5.42) 7.15 (0.37) 8.17 (5.66) 0.02 
TJC, mean (SD) 9.36 (7.12) 18.29 (5.01) 7.41 (5.93) <0.0001 
PtGH VAS  (cm), mean (SD) 6.13(2.48) 6.73 (2.15) 5.99 (2.53) 0.001 
PhGH VAS (cm), mean (SD) 5.34 (6.13) 5.85 (2.11) 5.22 (2.14) 0.004 
ESR (mm/h), mean (SD) 30.6 (25.2) 24.9 (20.5) 31.9 (25.9) 0.002 
CRP (mg/l), mean (SD) 21.4 (33.6) 17.4 (24.9) 22.3 (35.2) 0.071 
RF (%) 54.6 40 57.9 0.0004 
CCP (%) 45.7 29.2 49.3 <0.0001 
RF + CCP (%) 41.3 26.7 44.5 0.0003 
Erosions (%) 63.6 63.7 61.2 0.61 
Sharp score (SD) 6.29 (8.07) 5.12 (6.02) 6.54(8.44) 0.038 
Analgesics (%) 70.8 75.8 69.7 0.18 
NSAIDS (%) 90.7 89.2 91.1 0.52 
Corticosteroids (%) 13.0 14.2 12.8 0.68 
DMARDS Monotherapy (%) 7.7 7.5 7.7 1.0 
Combined DMARDS (%) 0.5 0.6 0 1.0 
Biologic DMARDS (%) 0 0 0 1.0 
Table 1. Demographic and disease characteristics at inclusion of the 668 
patients with rheumatoid arthritis (RA), grouped by fibromyalgic RA (FRA) 
presence. P-values denote the overall significance of differences between groups 
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calculated by a two-sample T-Test or by the chi-squared test. Obesity: 
(BMI≥30kg/m2); DAS28: 28-joint Disease Activity Score; the Simplified Disease 
Activity Index (SDAI) or the Clinical Disease Activity Index (CDAI); HAQ: Health 
Assessment Questionnaire; SJC: swollen joint counts, TJC: tender joint counts 
PtGH: patient global health; PhGH: physician global health; VAS: visual analog 
scale; RF: rheumatoid factor; CCP: Anti-citrullinated protein antibodies; ESR: 
erythrocyte sedimentation rate; CRP: C-reactive protein. 
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FRA 
 
No FRA 
Difference in 
Adjusted scores 
P value* 
DAS 28  3.5045 3.0541 0.4505 <0.0001 
SDAI 16.0891 11.5378 4.5514 <0.0001 
CDAI 14.9819 10.7510 4.2309 <0.0001 
HAQ 0.6293 0.4454 0.1739 0.0002 
SJC 2.32 2.18 0.14 0.5476 
TJC 7.97 3.27 4.70 0.0001 
PtGH VAS 3.82 3.01 0.81 <0.0001 
PhGH VAS 2.88 2.38 0.51 0.0044 
CRP 0.75 0.84 0.09 0.4147 
ESR 13.99 15.05 1.06 0.3602 
SHARP 7.3315 7.6756 0.341 0.3125 
Table 2. Comparison of rheumatoid arthritis activity scores and radiologic scores 
over follow up according to the presence of fibromyalgic RA (FRA). P-values 
denote the overall significance of a linear regression adjusting for baseline score, 
gender, age and smoking status. DAS28: 28-joint Disease Activity Score; 
Simplified Disease Activity Index (SDAI) or the Clinical Disease Activity Index 
(CDAI); HAQ: Health Assessment Questionnaire; SJC: swollen joint counts, TJC: 
tender joint counts PtGH: patient global health; PhGH: physician global health; 
VAS: visual analog scale; RF: rheumatoid factor; CCP: Anti-citrullinated protein 
antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein. 
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 Risk Ratio (95% Confidence Interval) P value* 
DAS low activity 0.77 (0.63, 0.94) 0.0101 
DAS remission 0.61 (0.46, 0.81) <0.0007 
SDAI remission 0.65 (0.43, 0.97) 0.0366 
CDAI remission 0.70 (0.49, 1.01) 0.0581 
Table 3. Low activity and remission attainment according to Fibromyalgic RA 
groups. P-values denote the overall significance of a log binomial regression 
adjusting for baseline score, gender, age and smoking status. DAS28 low 
activity; DAS28≤3.2; DAS28 remission: DAS28 ≤2.6; CDAI remission: CDAI≤2.8 
and of SDAI (SDAI≤3.3). 
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Figure 1. Flow diagram documenting number of patients in this study. RA 
includes patients that meet either ACR 1987 classification criteria or ACR/ 
EULAR 2010 classification criteria. FRA= Fibromyalgic rheumatoid arthritis. 
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Figure 2. DAS28 score at different time points grouped by fibromyalgic 
rheumatoid arthritis presence. 
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Figure 3. DAS28 core measures of disease activity at different time points 
grouped by fibromyalgic rheumatoid arthritis presence. A: Erythrocyte 
Sedimentation Rate (ESR),  B: C Reactive Protein (CRP), C: Tender Joint Count 
(TJC), D: Swollen Joint Count (SJC)  
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Figure 4. TJC – SJC difference during follow up in subjects grouped by FRA 
presence. 
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